Hengli® Chinese Botulinum Toxin Type A for Treatment of Patients With Overactive Bladder: A Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial

• Główni autorzy: Limin Liao (Autor), Qinggang Liu (Autor), Huiling Cong (Autor), Zhihui Xu (Autor), Enhui Li (Autor), Zhiliang Weng (Autor), Haihong Jiang (Autor), Ben Liu (Autor), Xiao Huang (Autor), Shujie Xia (Autor), Wei Wen (Autor), Juan Wu (Autor), Guowei Shi (Autor), Yang Wang (Autor), Peijun Li (Autor), Yang Yu (Autor), Zujun Fang (Autor), Jie Zheng (Autor), Ye Tian (Autor), Donghao Shang (Autor), Hanzhong Li (Autor), Zhongming Huang (Autor), Liqun Zhou (Autor), Yunxiang Xiao (Autor), Yaoguang Zhang (Autor), Jianlong Wang (Autor), Xiaodong Zhang (Autor), Peng Zhang (Autor), Dongwen Wang (Autor), Xuhui Zhang (Autor), Keji Xie (Autor), Bin Wang (Autor), Lulin Ma (Autor), Xiaojun Tian (Autor), Lijun Chen (Autor), Jinkai Dong (Autor)
• Format: Książka
• Wydane: Frontiers Media S.A., 2022-02-01T00:00:00Z.
• Hasła przedmiotowe: article
• Dostęp online: Connect to this object online.

Objective: To evaluate the efficacy and safety of Hengli® Chinese botulinum toxin type A (BTX-A; 100 U) in Chinese patients with overactive bladder.Methods: This study was a multicenter, randomized, double-blind, placebo-controlled trial in Chinese patients who were inadequately managed with anticho...